A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma
Untreated T-cell Angioimmunoblastic Lymphoma
About this trial
This is an interventional treatment trial for Untreated T-cell Angioimmunoblastic Lymphoma focused on measuring T-cell angioimmunoblastic lymphoma, Rituximab
Eligibility Criteria
Inclusion Criteria: Patients with histologically proven T-cell angioimmunoblastic lymphoma (AIL) on lymph node biopsy. Aged from 60 to 80 years. Patient not previously treated (except corticosteroids providing they have been initiated less than 10 days before inclusion). ECOG performance status 0 to 2. With a minimum of life expectancy > 3 months. Negative HIV, HBV and HCV serological tests < 4 weeks (except after vaccination). Having previously signed a written informed consent. Exclusion Criteria: Any other histological type of T-cell lymphoma. Central nervous system or meningeal involvement by lymphoma. Contra-indication to any drug included in the R-CHOP regimen. Concurrent severe disease (according to the investigator's decision). Active bacterial, viral or fungal infection. Poor renal function (serum creatinine level > 150 µmol/L) or impaired liver function tests (total bilirubin level > 30 µmol/L, transaminases > 2.5 upper normal limits) unless they are related to the lymphoma. Poor bone marrow reserve as defined by neutrophils < 1.5 x 109/L or platelets < 100 x 109/L, unless related to bone marrow infiltration. Any history of cancer during the last 5 years, with the exception of non basal cell carcinoma of the skin or in situ carcinoma of the cervix. Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study. Patient under tutelage.
Sites / Locations
- Hôpital Henri Mondor
- Hôpital Saint Louis
- Service d'Hématologie - Centre Hospitalier Lyon-Sud
- Centre Henri Becquerel
Arms of the Study
Arm 1
Experimental
Rituximab + CHOP
Rituximab + CHOP regimen Prednisone - Doxorubicine - Cyclophosphamide - Vincristine